非甾体消炎止痛药美洛昔康（Meloxicam）是全世界第一个上市的选择0性COX－2抑制剂，于1996年初由伯林格英格翰（BOEHRINGERRINGELHEIN）公司开发研制成功，并在德国首先上市，目前有片剂和针剂两种剂型。上市以来，两年销售即超过3记片，其独特的疗效及胃肠安全性探获临床医生 Meloxicam, the world’s first commercially available 0-selective COX-2 inhibitor, was successfully developed by BOEHRINGERRINGELHEIN in 1996 and was first used in Germany Listed, there are two formulations of tablets and injections. Since listing, two years of sales that more than 3 tablets, its unique efficacy and gastrointestinal safety of exploration clinicians